LB Pharmaceuticals Inc Common Stock

NASDAQ:LBRX

Biotechnology

Healthcare
$40.06 -1.30%

-$0.39 today

Market cap
$1.30B
Beta
0.71
P/E (TTM)
-21.4
EPS (TTM)
-$1.39
52W Low $13.36High $33.47

Volume 0.36M

Average 0.23M

LBRX Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

LB Pharmaceuticals Inc Common StockNASDAQ: LBRX

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow grows 186.2% year over year

Q1 FY2026 free cash flow of $23.32M (cash outflow) rose 186.2% year over year. Sequentially, it rose 28.5% from the prior quarter. Over 3 fiscal years it compounded at +134.7% a year.

Context

  • Free cash flow grew in size in 2 of the last 3 fiscal years.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$23.32M+28.5% QoQ
Last fiscal yearDec 2025
-$35.26M-34.5% YoY
LTMMar 2026
-$51.71M— YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+186.2%——
1 year-34.5%——
3-year CAGR+134.7%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(35.26M) USD
Year-over-year change
+34.5%

Free Cash Flow vs competitors

How LBRX compares with its peers on the latest reported figures

  • LBRX's LTM Mar 2026 free cash flow of $51.71M is the 9th largest of the 10 companies compared; the peer median is $164.26M.
  • Over three fiscal years its annual growth of +134.7% compares with a peer median of +36.4%.
LBRX Competitors Peer median
Free Cash Flow for LBRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NERVMinerva Neurosciences, Inc.LTM Jun 2026$18.78B —+718.3%—
DNLIDenali Therapeutics Inc.LTM Jun 2026$437.46M +18.9%+17.1%12138.1%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$193.4M -3.0%+21.4%—
DFTXDefinium Therapeutics, Inc.LTM Sep 2026$190.28M +67.0%+37.9%—
ACADACADIA Pharmaceuticals Inc.LTM Jun 2026$174.39M -6.8%—15.3%
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$164.26M +92.8%+71.8%—
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$80.71M +16.8%+192.3%403.5%
ANROAlto Neuroscience, Inc.LTM Mar 2026$62.86M +14.6%+34.8%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$51.71M —+134.7%—
GHRSGH Research PLCLTM Mar 2026$46.51M +12.6%+18.5%—
SPTXSeaport Therapeutics, Inc. Common Stock—— ———
Peer median (excluding LBRX) $164.26M+15.7%+36.4%403.5%

Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(14.35M)(6.28M)(63.1M)(25.21M)
Depreciation & Amortization2K4K91K321K
Deferred Income Tax0000
Stock-Based Compensation431K295K3.16M0
Change in Working Capital86K(1.31M)3.31M(13.65M)
Accounts Receivables0(154K)114K(268K)
Inventory0000
Accounts Payables000(910K)
Other Working Capital86K(1.16M)3.2M(12.47M)
Other Non-Cash Items11.1M(4.81M)3.49M3.33M
Operating Cash Flow(2.73M)(12.09M)(53.05M)(35.21M)
Capital Expenditures0(25K)(769K)(52K)
Acquisitions (Net)0000
Purchases of Investments0(33.99M)(29.75M)(44.84M)
Sales of Investments123K6M53.75M5M
Other Investing Activities0000
Investing Cash Flow123K(28.01M)23.23M(39.89M)
Debt Repayment25.01M725K00
Common Stock Issued000302.56M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities(2.95M)(2.05M)(1.69M)0
Financing Cash Flow22.96M33.68M38.32M302.56M
Effect of Forex Changes000(272K)
Net Change in Cash20.36M(6.43M)8.5M227.2M
Free Cash Flow(2.73M)(12.12M)(53.82M)(35.26M)

LB Pharmaceuticals Inc Common Stock

NASDAQ:LBRX

Intrinsic Alpha fair value

Locked

Current Price

$40.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.